Chagas disease persists as a global public health problem due to the high morbidity and
mortality burden. Despite the possibility of a cure and advances in transmission control …

Chagas disease (CD) is a worldwide problem, with over 8 million people infected in both
rural and urban areas. CD was first described over a century ago, but only two drugs are …

Introduction Chagas disease (CD) affects~ 7 million people worldwide. Benznidazole (BZN)
and nifurtimox (NFX) are the only approved drugs for CD chemotherapy. Although both …

Introduction Chagas disease affects 6–7 million people, mainly in the Americas, and
benznidazole is one of the two therapeutic options available. Trypanocide treatment aims to …

Chagas disease (CD) is caused by the flagellate protozoan Trypanosoma cruzi. It is
endemic in Latin America. Nowadays around 6 million people are affected worldwide, and …

Background People with Chagas disease may develop progressive and lethal heart
conditions. Drugs to eliminate the parasite Trypanosomacruzi (T cruzi) currently carry limited …

Introduction Chagas disease treatment relies on the lengthy administration of benznidazole
and/or nifurtimox, which have frequent toxicity associated. The disease, caused by the …

Objectives To determine the comparative efficacy and safety of a fixed dose of benznidazole
(BZN) with an adjusted‐dose for Trypanosoma cruzi‐seropositive adults without …

Chagas disease is a neglected disease that remains a public health threat, particularly in
Latin America. The most important treatment options are nitroimidazole derivatives, such as …

Due to the lack of specific vaccines, management of the trypanosomatid-caused neglected
tropical diseases (sleeping sickness, Chagas disease and leishmaniasis) relies exclusively …